PRO-002, a phase Ib dose-escalation study of NUC-1031 with carboplatin for recurrent ovarian cancerSarah P. Blagden, Essam Ghazaly, Ajithkumar Sukumaran et al.|Annals of Oncology|2017Cited by 2
A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer.Sarah P. Blagden, Essam Ghazaly, Ajithkumar Sukumaran et al.|Journal of Clinical Oncology|2016Cited by 2
Abstract B30: The RNA-binding protein LARP1 is a cancer therapeutic targetEssam Ghazaly, Sarah P. Blagden, Cristian Rodriguez‐Aguayo et al.|Cancer Research|2017Cited by 1
NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.Sarah P. Blagden, Jordan Berlin, T.R. Jeffry Evans et al.|Journal of Clinical Oncology|2018Cited by 1
The RNA-binding protein LARP1 is a cancer therapeutic targetEssam Ghazaly, Sarah P. Blagden, Cristian Rodriguez‐Aguayo et al.|Oxford University Research Archive (ORA) (University of Oxford)|2017Cited by 1